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Abstract
Diabetes mellitus is a multisystem group of disorders associated with insulin re-
sistance, metabolic stress, endothelial and adipose dysfunction and accelerated 
atherosclerosis. As the different players leading to atherosclerosis are known, the 
pathogenesis and eventually targets for treatment can be identified. The purpose 
of this review is to update the newer aspects of pathogenic factors as well as newer 
putative biomarkers in atherosclerosis. Hyperglycemia causes beta cell dysfunc-
tion, which results in impaired insulin secretion, endoplasmic reticulum stress and 
overproduction of reactive oxygen species. Lipotoxicity, or the accumulation of 
increased amounts of lipids in non-adipose tissue is found in the insulin produc-
ing pancreatic beta cells impairing their function. Gluco-lipotoxicity leads to the 
production of inflammatory cytokines, which damage the vasculature. Endothe-
lial dysfunction, which occurs due to all these insults can be studied by biochemi-
cal alterations and by non-invasive imaging techniques. In addition, epigenetic 
changes have been identified in the pathogenesis.  More recent biomediators 
were identified to be involved in the process of atherogenesis including adiponec-
tin, leptin, resistin, adropin, visfatin, hepatokines, bone morphogenetic protein, 
nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF),  families of 
micro RNAs, extracellular vesicles (exosomes, ectosomes) and a variety of environ-
mental factors. In view of managing conventional risk factors has not prevented 
atherosclerotic complications, the better understanding the role of pro- and anti-
atherogenic factors may allow the development of novel drugs to modify them. 
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Introduction
The biological action of insulin is initiat-
ed when it binds to the insulin receptor 
at the surface of target cells. This leads to 
the receptor being autophosphorylated, 
which in turn functions as a tyrosine ki-
nase, activating two different pathways. 
Acting via the phosphatidylinositol 
3-kinase Akt pathway it phosphoryl-
ates IRS-1 to 4, a member of the insu-
lin receptor substrate family. The IRS 
contains both tyrosine phosphorylation 
and Ser/Thr phosphorylation sites. A 
balance between these two components 
regulates IRS function (1). Tyrosine-
phosphorylated IRS further binds to 
the adapter protein P13K, activating its 
catalytic subunit at P13K, leading to the 
eventual metabolic actions of insulin.
Besides the autophosphorylation 
pathway, there is a separate and paral-
lel mitogen-activated protein kinase 
(MAPK) pathway. Here the activation of 
insulin receptor leads to phosphoryla-
tion of intracellular substrate containing 
Shc protein, which in turn binds to the 
growth factor receptor, the activation of 
GTP exchange factor, which regulates 
growth and mitogenesis.
P13K/Akt primarily acts in tissues 
where there is rapid stimulation of glu-
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cose transport, synthesis of lipids and in energy metabolism (1). 
There is tissue specificity: IRS-1 proteins are associated with 
glucose homeostasis in adipocytes, skeletal muscle cells and 
pancreatic beta cells; IRS-2 in liver metabolism, and IRS-3 in 
adipose tissue. 
Insulin resistance is associated with dysregulation of glucose, 
lipid and insulin regulation;  cellular proliferation and apopto-
sis and production of gaseous signaling molecule  such as nitric 
oxide (NO) are also disturbed (2). Vascular cell dysfunction im-
pairs compliance, and initiates inflammation leading to athero-
sclerosis. Atherosclerosis results from an interplay of endothe-
lial dysfunction, subendothelial retention of lipids, and adipose 
dysfunction (see below); this leads to a chronic inflammatory 
response which destroys the intima, resulting in vascular throm-
bosis and ischemia (3). 
Metabolic stress: glucotoxicity, lipotoxicity  
and gluco-lipotoxicity
Among components of the metabolic syndrome which under-
lie insulin resistance, dyslipidemia, dysglycemia and obesity are 
crucial. 
Glucotoxicity
Glucotoxicity refers to the “structural and functional damage in 
the pancreatic beta-cells caused by chronic hyperglycemia” (4). 
Elevation of glucose levels beyond physiological levels induces 
the expression of pro-apoptotic signals such as endoplasmic 
reticulum stress, oxidative stress and dysfunction of the mito-
chondria (4). Exposed to increased demands of insulin secre-
tion as in hyperglycemic conditions, endoplasmic reticulum of 
beta cells face increased demand for synthesis of proinsulin, a 
precursor of insulin. This is associated with increased flux of 
protein through the endoplasmic reticulum. When the capacity 
of the endoplasmic reticulum is overwhelmed (ER stress), syn-
thesis and delivery of proteins is impaired, an unfolded protein 
response is triggered to restore the balance. When the restora-
tive capacity is exceeded, apoptotic signals to the beta cells are 
transmitted by stress kinases and transcription factors (MAPK, 
JNK, caspase-12). 
In a euglycemic state, ATP-sensitive potassium channels are 
closed, with a release of calcium; in  long standing hypergly-
cemic conditions, chronic release of calcium release leads to a 
pro-apoptopic state. Oxidative stress results in overproduction 
and accumulation of reactive oxygen species (ROS) and reactive 
nitrogen species (RNS). Reactive oxygen species are normally 
formed during cellular metabolism, comprising of superox-
ides, peroxides and hydroxyl moieties. These are neutralized by 
naturall antioxidants such as glutathione peroxidase, catalase, 
thioredoxin and superoxide dismutase. When the RNS and ROS 
overwhelm the native antioxidant capacity of the pancreatic beta 
cells, the, beta cells are damaged. Stress-induced pathways are 
activated leading to cellular apoptosis via nuclear factor-kB c-
Jun N-terminal kinase 9jnk0 stress kinases and hexosamines (1). 
Lipotoxicity
Lipotoxicity refers to the accumulation of increased amounts of 
lipids in non-adipose tissue, which leads to cellular dysfunction 
and death. Normally, free fatty acids (FFAs) are either synthe-
sized de novo or are transported across the cell membrane for 
their physiological roles. Excess quantities of FFAs are esterified 
and stored in lipid droplets as triglycerides, as efficient energy 
stores in times of starvation. Adipose tissue is chiefly endowed 
with the ability to store large quantities of free fatty acids in the 
form of cytosolic droplets. Lipotoxicity results when excess fatty 
acids spill over and exceed the storage capacity of extra-adipo-
cyte tissues. Cellular function is disturbed leading them to their 
death. In the pancreatic islet function is inhibited due to lipid 
(5). Dyslipidemia is a key component of insulin resistance (‘met-
abolic’) syndrome when excess lipids accumulate in tissues such 
as liver and heart, often preceding organ dysfunction. Ectopic 
lipid deposition in the skeletal muscle is a marker of insulin 
resistance. Lipid derivatives such as diacylglycerols, fatty acyl-
CoAs and ceramide localization, composition and turnover may 
be the pathogenic factors (6). Besides rendering cells suscepti-
ble to apoptosis, lipotoxicity also enhances systemic low-grade 
inflammation (7). Other adverse effects of lipotoxicity include 
membrane detergent effects, impaired ability to suppress lipoly-
sis in adjacent cells, beta oxidation of fatty acids and effects on 
ceramide (8). Putative pathogenic mechanisms of nonesterified 
fatty acids (NEFA) are summarized in Table 1





Activation of protein kinase C, NF-KB
Endoplasmic reticulum stress




Lipid-induced toxicity on pancreatic beta cells occurs only in 
the presence of hyperglycemia – a concept called glucolipotoxic­
ity. In the presence of high glucose levels, fatty acids accumulate 
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in the mitochondria; when persistent, beta cell function is im-
paired leading to apoptosis (1). 
Atherosclerosis
While atherosclerosis essentially results from the accumulation 
of lipid in the subendothelial space, other contributions include 
mechanotransduction, inflammation in endothelial cells and the 
phenotypic switching of smooth muscle cells (3).  Insulin resist-
ance and endothelial dysfunction together lead to atherosclero-
sis and vascular disease. The endothelium, which forms the in-
ner lining of blood vessels has multiple functions; it has been de-
scribed as a paracrine, autocrine and endocrine organ responsi-
ble for vascular homeostasis (10, 11). It is principally influenced 
by insulin which affects both vasodilators (e.g. prostaglandins 
PG12) and vasoconstrictors (e.g. angiotensiin II). Through the 
activation of P13-K/Akt pathway, eNOS is phosphorylated and 
there is conversion of L-arginine to L-citruline and NO.  The 
latter not only has vasodilatory roles, but has protective action 
on endothelium by reducing cell adhesion molecules, platelet 
aggregation and the synthesis of proinflammatory cytokines 
(10).  Decreased NO can induce abnormalities found in obesity, 
diabetes and cardiovascular disease (12). The role of G-protein-
coupled receptor kinase 2 (GRK2) in the progression of cardio-
vascular disease has been recognised. High levels of GRK2 may 
be the mediator of endothelial dysfunction by decreasing the 
intracellular levels of NO. In addition, advanced glycated end 
products (AGE) which accumulate in hyperglycemic conditions 
further affect the functional capacity of the blood vessels (13).
Reactive oxygen species
Reactive oxygen species have a critical role in causing endothe-
lial dysfunction (14). Harmful ROS molecules (cf Jacob and 
Manoj in this volume of Adipobiology) in the vessel wall include 
H2O2, O2, OH and ONOO. Hypoxia disturbs the fine balance be-
tween ROS production during mitochondrial electron transport. 
Instead of ROS being quenched, there is a depletion of ATP, mi-
tochondrial depolarization, acidosis and ultimately, cell death. 
Besides, ROS have an adverse effect on arterial wall remodeling 
(14) via proliferation of smooth muscle cell and induction of in-
flammation. Repeated chronic mechanical stress generates free 
radicals which aid in adhesion of monocytes.  Recent studies 
have shown that endothelial dysfunction is worsened by lipid 
peroxidation or by decreased antioxidants (15). In coronary ar-
tery disease, antioxidant enzymes are upregulated in the early 
stages, but they are overwhelmed by chronic exposure to ROS. 
Nrf2 was is a transcription factor binding to Keap1-antioxidant 
signal that promotes transcription of antioxidant genes (16).
Endothelial dysfunction in diabetic vascular disease
The earliest stage of endothelial dysfunction results from an 
impaired availability of NO. It progresses to impaired endothe-
lium-mediated vessel regulation, poor fibrinolytic action, in-
creased growth factor production, adhesion molecules and 
inflammatory genes, leading to oxidative stress and enhanced 
permeability (17). Pro-atherogenic properties due to endothe-
lial dysfunction result from both a loss of its protective ability 
and enhanced pro-atherothrombotic properties. The endothelial 
dysfunction in diabetes can be summarized as follows:  impaired 
vasodilation, increased oxidative stress, pro-coagulant and pro-
inflammatory environment resulting in poor repair in the face of 
increased cellular damage (17).
Clinical assessment of endothelial dysfunction
Endothelial dysfunction was first studied by invasive methods 
in the coronary vasculature (12). Non-invasive procedure com-
monly used in clinical studies include flow-mediated dilation 
was used as a surrogate to assess endothelial function (18).  It is 
safe, non-invasive, cost-effective and reproducible.  Other meth-
ods include low-flow mediated constriction and endothelial 
peripheral arterial tonometry. While the former provides infor-
mation about the resting endothelial activity, the latter provides 
information about changes in finger arterial pulse-wave ampli-
tude during reactive hyperemia. Other invasive methods are ve-
nous occlusion plethysmography, which needs canulation of the 
brachial artery is used to measure changes in the volume of the 
pre-constricted vein to different substances.
Biochemical markers of endothelial function include 
E-selectin, ICAM-1, VCAM-1, interleukin-1, tumour necrosis 
factor a, interferon g, monocyte chemoattractant protein and 
tissue plasminogen activator. Measurement of urinary micro-
albuminuria is a commonly employed, if non-specific method. 
Recently, asymmetrical dimethylarginine (ADMA) was shown 
to be a promising independent risk factor (19). ADMA, which 
is synthesized in the body, inhibits eNOS resulting in low NO 
production.  Increased levels of ADMA were reported in athero-
sclerotic vascular disease (12). 
An intriguing new marker of endothelial function has 
been identified: endothelial microparticles (ectosomes) (20). 
Circulating endothelial microparticles (EMPs, a type of extra-
cellular vesicles) which carry biologically active compounds act 
as signals between different cells. They could serve as biologi-
cal markers of vascular endothelial dysfunction. Levels of EMPs 
were higher in diabetes and correlated with diabetes related 
complications (20). 
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Obesity, inflammation and immune interactions
Evolutionarily, survival of multicellular organisms depended on 
the ability to protect themselves from pathogens, to heal when 
attacked, and to store energy for times of need. The basic re-
quirement was for close cross-talk between  immune and met-
abolic systems (21). While such association was favourable in 
normal conditions, problems arose in conditions of metabolic 
stress. The adverse inflammatory conditions linked with obesity 
– diabetes, fatty liver and atherosclerosis occur in conditions of 
metabolic overload. 
The inflammatory cytokine tumor necrosis factor-alpha 
(TNF-α) was shown to be overexpressed in animal models of 
obesity, leading to impaired insulin action. A variety of other cy-
tokine players were recognized at the intersection of immunity 
and metabolism (21): interleukins, leptin, adiponectin, visfatin, 
resistin, and C-reactive protein. 
Which came first: obesity or inflammation? Evidence appears 
to point toward inflammation being the principal player result-
ing  in obesity associated insulin resistance, hyperglycemia and 
dysglycemia. 
Recent studies on inflammatory mediators
Resistin is an adipokine which is primarily secreted by human 
macrophages. Increased levels of this adipokine are associated 
with insulin resistance, diabetes mellitus and cardiovascular dis-
ease (22). It promotes endothelial dysfunction, proliferation of 
smooth muscle, inflammation in the arterial wall and endothe-
lial dysfunction. 
Adropin a newly identified protein has critical roles in en-
ergy homeostasis and in maintaining insulin sensitivity. It is a 
regulator of endothelial cells and can be used as a circulating 
biomarker. Low adropin levels were shown to be a risk factor of 
heart disease (23). 
Visfatin, a cytokine secreted by adipose tissue could be a me-
diator among inflammation, endothelial dysfunction leading to 
atherosclerosis and to plaque instability in acute coronary syn-
dromes. It is being evaluated as a possible plasma biomarker for 
inflammatory states (24). 
GDF­15 is a recently recognized cytokine that is released in 
response to stress from a range of cells: adipocytes, macrophag-
es, smooth muscle cells and endothelial cells. Its level increases 
in inflammatory conditions, and can serve as a marker of cardio-
vascular disease (25). It may be protective in some and patho-
genic in others. GDF-15 is a promising biomarker and a poten-
tial drug target against vascular disease
Adiponectin is a long recognized anti-atherogenic adipokine 
which acts on the vessel wall to prevent inflammation. It modi-
fies intracellular signal pathways in blood vessels (26), with in-
sulin sensitizing properties expressed via adiponectin receptors 
AdipoR1 and AdipoR2. They form potential targets for pharma-
cologic modulation in metabolic syndrome and diabetes (27). 
Hepatokines,  proteins primarily secreted by the liver, influ-
ence the progression of atherosclerosis by altering endothelial 
function. They influence both glucose and lipid metabolism and 
can affect atherosclerosis by modulating inflammatory path-
ways. Representative hepatokines include fibroblast growth 
factor 21, fetuin A, selenoprotein P (28). These are important 
because of the increasing recognition of non-alcoholic fatty acid 
disease, a hepatic manifestation of metabolic syndrome which is 
associated with the development of type 2 diabetes mellitus and 
cardiovascular disease. 
Bone morphogenetic protein (BMP) family plays important 
functions in endothelium of vessels by increasing formation of 
blood vessels and by modifying stress due to blood flow and oxi-
dation. Impaired regulation of BMPs was linked with vascular 
disease including atherosclerosis. It influences endothelial func-
tion by acting through endothelial signaling (29). 
Other potential pathogenic mechanisms
MicroRNAs (miRNAs) are non-coding RNA molecules that 
modulate the stability and/or the translational efficiency of tar-
get messenger RNAs (30). miRNAs were proposed to regulate 
gene expression following oxidative stress leading to atheroscle-
rosis (31). Specifically the miR-221/222 cluster acts to regulate 
endothelial cells and maintain endothelial integrity. In athero-
sclerotic vessels this cluster promotes formation of neointima 
(32). They could also have effects on glucose and fat metabolism 
in other tissues. 
Mechanotransduction, as mentioned earlier, refers to the 
pathways modulating atherogenesis because of disturbances in 
laminar blood flow (33). A number of pathways are described: 
mitogen-activated protein kinases/extracellular signal-regulated 
kinase 5/Kruppel-likd factor 2 signaling, extracellular signal-
regulated kionase/ peroxisome proliferator-activated receptor 
signaling. Dissecting the roles of each would help in designing 
therapeutic interventions (33). 
Mental stress has now been recognised to accompany and 
to lead to insulin resistance and type 2 diabetes mellitus (34). 
Stress, including depression could exert their adverse effects via 
inappropriate formation of reactive oxygen species and the at-
tendant downstream effects (35). 
Epigenetic factors interact with transcription factors by re-
programming the transcriptome of the vascular endothelial cells 
(36). There could thus be involvement of epigenetic mechanisms 
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in modulating endothelial injury during the atherogenic process. 
Air pollution is a surprising new entrant that can cause insulin 
resistance through its effects on inflammation, endoplasmic re-
ticulum stress and oxidative stress (37). Being ubiquitous in ur-
ban areas, air pollutants can contribute to endothelial dysfunc-
tion associated with diabetes mellitus, in addition to other risk 
factors.
Human knock­outs have been receiving increasing atten-
tion in understanding the physiological role of proteins, and 
in designing interventions to influence their function. Human 
knock-outs refers to identifying ‘normal’ persons who lack a 
particular enzyme or protein, that is, without manifesting any 
signs or symptoms of disease. A variety of such enzyme defi-
ciency states have been identified (38-40). These enzymes influ-
ence lipid metabolism and thereby modify the oxidative stress. 
Interestingly, pharmacological agents to lower the level of the 
enzyme ANGPTL3 (39, 41) was shown to lower blood lipopro-
tein levels with a potential for reducing the risk of atheroscle-
rosis in an animal model, opening the way for innovative drug 
development in humans (41). 
Overview of the contributions to cell biology  
of atherosclerosis
Atherosclerosis is a leading cause of disease and death in both 
developed and developing countries. The endothelial lining of 
vessels, a dynamic entity, serves as the interface with blood flow 
and may be considered a ‘transducer of both humoral and me-
chanical stimuli (42). Endothelial dysfunction is triggered by 
biomechanical forces due to disturbed blood flow. The impor-
tance of understanding the pathogenesis is to devise preventive 
measures by reversing endothelial dysfunction and correcting 
local lipid changes. 
Noteworthy, putative metabotrophic mediators acting on 
glucose and lipid metabolism consist of neurotrophins such 
as nerve growth factor (NGF) and brain-derived nerve factor 
(BDNF) (43). While it was originally identified to be important 
in neuronal growth, NGF and BDNF were shown to improve 
survival and activity of non-neuronal cells also, including vas-
cular endothelium. In clinical studies of subjects with advanced 
metabolic syndrome (44) and with acute coronary syndromes 
(45), the circulating levels of NGF and BDNF were lower com-
pared to controls. 
Further, there is an intimate interaction among vascular biol-
ogy, adipobiology and neuroimmunology, which has been called 
‘triactome’ (46). It brings into focus the importance of consider-
ing the four coats of the blood vessel: intima, media, adventi-
tia, and adiposa (perivascular adipose tissue). The “triactome” 
forms a potential target for the development of drugs against 
atherosclerosis. 
Ectosomes,  extracellular vesicles resulting from plasma mem-
brane shedding, are found across life forms (47). Subjects with 
type 2 diabetes showed differences in the pro-angiogenic and 
anti-angiogenetic miRNA in ectosomes, forming potential drug 
targets (47). Both ectosomes and exosomes transfer signals to 
distant cells. While ectosomes are released from the plasma 
membrane, exosomes are released from multivesicular bodies 
(48). 
Unique signaling pathways for diabetic vascular complica-
tions were explored in an effort to identify new targets for in-
tervention. Levels of gasotransmitters such as hydrogen sulfide 
(48a), NO, and carbon monoxide are altered in diabetes. 
Traditional risk factors such as obesity, smoking and hyperten-
sion participate in reduced bioavailability of these gastrotrans-
mitters. Modulating these is an exciting new therapeutic option, 
as they are also released from perivascular adipose tissue (49, 
50).
The link between metabolic syndrome via endotoxins and 
low-grade systemic inflammation is well known (15). Interesting 
ways in which gut microbiota can mediate the hyperglycemic ef-
fects of organophosphate insecticides are explored (51)
Globally, tuberculosis is a common complication of diabetes 
needing attention. Interestingly, adipose tissue could serve as a 
niche storage for Mycobacterium tuberculosis. It has the potential 
to modify the expression of genes related to the stress response 
(52). 
Intriguingly, BCG vaccine, traditionally used against tuber-
culosis infection, given as two doses to subjects with type 1 dia-
betes lowered glycosylated hemoglobin. The effect was seen after 
three years, and persisted for five years. A shift of glucose me-
tabolism from oxidative phosphorylation to aerobic glycolysis 
was observed (53). 
Psychological stress and disturbances of sleep lead to obesity, 
insulin resistance and cardiovascular morbidity (54, 55). Built 
environment is related multiple adverse effects of stress, and 
availability of space and time for physical exercise and relaxa-
tion. It also contributes to modifying the exposure to environ-
mental air pollutants. All these have roles to play a role in the 
pathogenesis of diabetes and its complications (56-58). 
Conventional risk factor management (59) has not been re-
ally helpful, as yet. Leads toward non-conventional factors, 
interventions targeting them, or improving the application of 
available modalities is necessary.
Genome wise analysis studies provide leads, but have not 
given the kind of transformative treatments as originally antici-
pated. Approaching the suspects by network analysis is the way 
ahead (60), along with evaluating proximate and upstream sig-
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nals emanating from the genome. Understanding the beneficial 
aggressive glycemic control over long-term vasculopathy is lead-
ing to role of epigenetic changes such as DNA methylation, post-
translational chromatin modifications and RNAs serving as the 
link between the environment and genes (61)
Conclusion
The major aim of understanding pathobiology is to prevent the 
occurrence of disease. Physical exercise, prevention of over-
weight and obesity, smoking stopping and diet control are aimed 
at correcting risk factors. In addition, drugs to normalize hyper-
tension, dyslipidemia, diabetes, obesity and other complications 
attempt to both prevent and treat endothelial (10-13) and adi-
pose (43, 46, 48a) dysfunction.
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